Proximal tubular renal dysfunction or damage in HIV-infected patients

AIDS Reviews

Volumn 14, Issue 3, 2012, Pages 179-187

  Del Palacio, María ^a   Romero, Sara ^b   Casado, Jose L ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Hospital Universitario del Sureste de Madrid   (Spain)

Author keywords

Beta 2 microglobulin; Biomarkers; Retinol binding protein; Tenofovir; Tubular dysfunction

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CREATININE; CYSTATIN C; FATTY ACID BINDING PROTEIN; GLUTATHIONE TRANSFERASE; INTERLEUKIN 18; KIDNEY INJURY MOLECULE 1; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; RETINOL BINDING PROTEIN; RITONAVIR; TENOFOVIR; TUMOR NECROSIS FACTOR RECEPTOR 1; VASCULAR CELL ADHESION MOLECULE 1;

BETA 2 MICROGLOBULIN URINE LEVEL; CELL DAMAGE; CLINICAL FEATURE; CREATININE BLOOD LEVEL; FANCONI RENOTUBULAR SYNDROME; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; KIDNEY TUBULE DISORDER; REVIEW;

ACETYLGLUCOSAMINIDASE; ACQUIRED IMMUNODEFICIENCY SYNDROME; ACUTE-PHASE PROTEINS; ADENINE; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CREATININE; DISEASE PROGRESSION; FANCONI SYNDROME; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY TUBULES, PROXIMAL; LIPOCALINS; MALE; MEMBRANE GLYCOPROTEINS; PHOSPHONIC ACIDS; PROTO-ONCOGENE PROTEINS; RECEPTORS, VIRUS; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 84864663441     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Szczech L, Hoover D, Feldman J, et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis. 2004;39:1199-206. (Pubitemid 40169320)
2. Wyatt C, Winston J, Malvestutto C, et al. Chronic kidney disease in HIV infection: an urban epidemic. AIDS. 2007;21:2101-3. (Pubitemid 47462160)
3. Mocroft A, Kirk O, Gatell J, et al. Chronic renal failure among HIV-1-infected patients. AIDS. 2007;21:1119-27. (Pubitemid 46763282)
4. Szczech L, Gange S, van der Horst C, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int. 2002;61:195-202. (Pubitemid 34075147)
5. Gupta S, Mamlin B, Johnson C, Dollins M, Topf J, Dubé M. Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol. 2004;61:1-6. (Pubitemid 38100837)
6. Gardner L, Holmberg S, Williamson J, et al. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:203-9. (Pubitemid 36222723)
7. Wyatt C, Klotman P. HIV-1 and HIV-associated nephropathy 25 years later. Clin J Am Soc Nephrol. 2007;2(Suppl 1):S20-4.
8. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36:1070-3. (Pubitemid 36513295)
9. James C, Steinhaus M, Szabo S, Dressier R. Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy. 2004;24:415-18. (Pubitemid 38298769)
10. Malik A, Abraham P, Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment - case report and review of literature. J Infect. 2005;51:E61-5. (Pubitemid 40984370)
11. Fux C, Cavassini M. Tenofovir and PI use are associated with an increased prevalence of proximal renal tubular dysfunction in the Swiss HIV Cohort Study. 16th CROI, 2009, Montreal, Canada. [Abstract 743].
12. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23:689-96.
13. Kohler J, Hosseini S, Hoying-Brandt A, et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest. 2009;89:513-19.
14. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197:102-8. (Pubitemid 351263473)
15. Cihlar T, Ho E, Lin D, Mulato A. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001;20:641-8. (Pubitemid 32821831)
16. Ray A, Cihlar T, Robinson K, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50:3297-304. (Pubitemid 44527501)
17. Rodriguez-Novoa S, Alvarez E, Labarga P, Soriano V. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf. 2010;9:545-59.
18. Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr. 2004;37:1489-95. (Pubitemid 39602339)
19. Izzedine H, Isnard-Bagnis C, Hulot J, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS. 2004;18:1074-6. (Pubitemid 38591202)
20. Earle K, Seneviratne T, Shaker J, Shoback D. Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res. 2004;19:714-21. (Pubitemid 41094381)
21. Gupta S. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS. 2008;22:99-103. (Pubitemid 351252586)
22. Day S, Leake Date H, Bannister A, Hankins M, Fisher M. Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice. J Acquir Immune Defic Syndr. 2005;38:301-4. (Pubitemid 40333495)
23. Woodward C, Hall A, Williams I, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2009;10:482-7.
24. Hall A, Edwards S, Lapsley M, et al. Subclinical tubular injury in HIVinfected individuals on antiretroviral therapy: a cross-sectional analysis. Am J Kidney Dis. 2009;54:1034-42.
25. Kinai E, Hanabusa H. Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels. AIDS. 2005;19:2031-3. (Pubitemid 41669029)
26. Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses. 2009;25:387-94.
27. Herlitz L, Mohan S, Stokes M, Radhakrishnan J, D'Agati V, Markowitz G. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int. 2010;78:1171-7.
28. Kabanda A, Vandercam B, Bernard A, Lauwerys R, van Ypersele de Strihou C. Low molecular weight proteinuria in human immunodeficiency virus-infected patients. Am J Kidney Dis. 996;27:803-8.
29. Miller R, Shahmonesh M, Hanna M, Unwin R, Schapira A, Weller I. Polyphenotypic expression of mitochondrial toxicity caused by nucleoside reverse transcriptase inhibitors. Antivir Ther. 2003;8:253-7. (Pubitemid 36960901)
30. Shepp D, Curtis S, Rooney J. Causes and consequences of hypokalemia in patients on tenofovir disoproxil fumarate. AIDS. 2007;21:1479-81. (Pubitemid 46988009)
31. Dauchy F, Lawson-Ayayi S, de La Faille R, et al. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int. 2011;80:302-9.
32. Vaidya V, Ferguson M, Bonventre J. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol. 2008;48:463-93. (Pubitemid 351738161)
33. Ando M, Yanagisawa N, Ajisawa A, Tsuchiya K, Nitta K. Kidney tubular damage in the absence of glomerular defects in HIV-infected patients on highly active antiretroviral therapy. Nephrol Dial Transplant. 2011;26:3224-9.
34. Tesch G. Review: Serum and urine biomarkers of kidney disease: A pathophysiological perspective. Nephrology (Carlton). 2010;15:609-16.
35. Urbschat A, Obermuller N, Haferkamp A. Biomarkers of kidney injury. Biomarkers. 2011;16(Suppl 1):S22-30.
36. Dieterle F, Sistare F, Goodsaid F, et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol. 2010;28:455-62.
37. Cruz D, de Geus H, Bagshaw S. Biomarker strategies to predict need for renal replacement therapy in acute kidney injury. Semin Dial. 2011;24:124-31.
38. Maack T. Renal handling of low molecular weight proteins. Am J Med. 1975;58:57-64.
39. Papaleo A, Warszawski J, Salomon R, et al. Increased beta-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir. Pediatr Infect Dis J. 2007;26:949-51. (Pubitemid 47494169)
40. Gatanaga H, Tachikawa N, Kikuchi Y, et al. Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses. 2006;22:744-8. (Pubitemid 44735000)
41. Curhan G. Cystatin C: a marker of renal function or something more? Clin Chem. 2005;51:293-4. (Pubitemid 40175796)
42. Jaafar A, Seronie-Vivien S, Malard L, Massip P, Chatelut E, Tack I. Urinary cystatin C can improve the renal safety follow-up of tenofovirtreated patients. AIDS. 2009;23:257-9.
43. Hall A, Hendry B, Nitsch D, Connolly J. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57:773-80.
44. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and metaanalysis. Am J Kidney Dis. 2009;54:1012-24.
45. Kuwabara T, Mori K, Mukoyama M, et al. Urinary neutrophil gelatinaseassociated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int. 2009;75:285-94.
46. Landro L, Damas J, Flo T, et al. Decreased serum lipocalin-2 levels in human immunodeficiency virus-infected patients: increase during highly active anti-retroviral therapy. Clin Exp Immunol. 2008;152:57-63. (Pubitemid 351347544)
47. Estrella M, Fine D, Atta M. Recent developments in HIV-related kidney disease. HIV Ther. 2010;4:589-603.
48. Sola-Del Valle D, Mohan S, Cheng J, et al. Urinary NGAL is a useful clinical biomarker of HIV-associated nephropathy. Nephrol Dial Transplant. 2011;26:2387-90.
49. Liangos O, Perianayagam M, Vaidya V, et al. Urinary N-acetyl-beta-(D)- glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol. 2007;18:904-12. (Pubitemid 46434507)
50. Marchewka Z, Kuzniar J, Dlugosz A. Enzymuria and beta2-microglobulinuria in the assessment of the influence of proteinuria on the progression of glomerulopathies. Int Urol Nephrol. 2001;33:673-6. (Pubitemid 35282660)
51. Post F, Moyle G, Stellbrink H, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55:49-57.
52. Maggi P, Montinaro V, Bellacosa C, et al. Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir. AIDS Patient Care STDS. 2011;26:5-11.
53. Portilla D, Dent C, Sugaya T, et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2008;73:465-72. (Pubitemid 351186293)
54. Kamijo A, Sugaya T, Hikawa A, et al. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem. 2006;284:175-82. (Pubitemid 44404425)
55. Bonventre J. Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. Nephrol Dial Transplant. 2009;24:3265-8.
56. Jaroszewicz J, Wiercinska-Drapalo A, Lapinski T, Prokopowicz D, Rogalska M, Parfieniuk A. Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART duration. Antivir Ther. 2006;11:641-5. (Pubitemid 44277430)
57. Iglesias J, Marik P, Levine J. Elevated serum levels of the type I and type II receptors for tumor necrosis factor-alpha as predictive factors for ARF in patients with septic shock. Am J Kidney Dis. 2003;41:62-75. (Pubitemid 36043352)
58. Parikh C, Mishra J, Thiessen-Philbrook H, et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2006;70:199-203. (Pubitemid 44000139)
59. Calmy A, Fux CA, Norris R, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis. 2009;200:1746-54.
60. Reynes J, Peyriere H, De Boever C, Le Moing V. Renal tubular injury and severe hypophosphoremia (Fanconi syndrome) associated with tenofovir therapy [poster 717]. Program and Abstracts of the 10th CROI, 2003. Boston, USA.
61. Blick G, Garton T, Hatton E, Lopez R. Tenofovir may cause hypophosphatemia in HIV/AIDS patients with prior adefovir-induced renal tubular acidosis [poster 718]. Program and Abstracts of the 10th CROI, 2003. Boston, USA.
62. Estrella M, Fine D. Screening for chronic kidney disease in HIV-infected patients. Adv Chronic Kidney Dis. 2010;17:26-35.